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Asthma is a chronic inflammatory con-
dition of the airways characterized by
reversible airway obstruction, airway
hyperresponsiveness (AHR) to normally
harmless stimuli and airway inflamma-
tion. Eosinophilic asthma is a phenotype
of the condition characterized by increased
blood or sputum eosinophils whose num-
bers correlate with disease severity. Release
of their potent pro-inflammatory arsenal
by infiltrating tissue eosinophils, including
granule-derived basic proteins, mediators,
cytokines and chemokines, contributes
to airway inflammation, and lung tissue
remodeling that includes airway thick-
ening and fibrosis. More recent evidence
suggests that in addition to their role as
degranulating effector cells, eosinophils
have the capacity to act as antigen
presenting cells resulting in T cell pro-
liferation and activation (Blanchard and
Rothenberg, 2009). Eosinophil extrava-
sation from the post-capillary venules,
migration within the interstitium, cel-
lular activation and tissue retention are
controlled by cell adhesion molecules,
i.e., selections, integrins and members of
the immunoglobulin superfamily (Barthel
et al., 2008; Barnes, 2011). The expres-
sion and function of these adhesion
molecules and the subsequent chemotac-
tic attraction and activation of infiltrating
pro-inflammatory cells are controlled by
a myriad of cytokines, chemokines and
mediators with the Th2 cytokines IL-4,
IL-5, and IL-13 representing essential and
central coordinators of asthmatic inflam-
mation (Barrett and Austen, 2009; Walsh,
2010). Thus, modulating the cytokine
network in asthma with biological ther-
apy targeted to patients with particular
eosinophilic phenotypes represents a
plausible paradigm for treatment of this
important condition (Petsky et al., 2007;
Barnes, 2008; Desai and Brightling, 2009;
Walsh, 2011).
INTERLEUKIN-5
The crucial role of IL-5 in the develop-
ment and release of eosinophils from the
bone marrow, their enhanced adhesion to
endothelial cells lining the post-capillary
venules and their activation and secre-
tion in the tissues has been known for
many years (Egan et al., 1996). IL-5 was
identified as a target to prevent or blunt
eosinophil-mediated inflammation in
patients with asthma, leading to the devel-
opment of humanized anti-IL-5mAb such
as mepolizumab, reslizumab and benral-
izumab (Long, 2009; Molfino et al., 2012).
Early clinical trials with mepolizumab
(GlaxoSmithKline plc) reported signif-
icant reductions of blood and sputum
eosinophils but clinical outcomes were dis-
appointing (Leckie et al., 2000; Flood-Page
et al., 2003; Kips et al., 2003; Flood-
Page et al., 2007). However, these studies
all used subjects recruited on the basis
of clinical and physiological character-
istics not associated with the presence
of eosinophilic airway inflammation
(O’Byrne, 2007). Two more recent studies
in highly selected asthma patient pop-
ulations with a demonstrable sputum
eosinophila reported that mepolizumab
treatment not only reduced eosinophil
numbers in the blood and sputum but also
gave a significant reduction in asthma
exacerbations and also demonstrated
that mepolizumab attenuates aspects of
eosinophil-induced airway inflammation
refractive to glucocorticoid (GC) therapy
(Haldar et al., 2009; Nair et al., 2009).
A recent randomized, placebo-controlled
trial evaluated intravenous reslizumab in
patients with poorly controlled asthma, a
sputum eosinophilia greater than 3% and
who were taking high-dose inhaled GC.
The reslizumab group exhibited a signifi-
cant decrease in sputum eosinophilia with
a non-significant trend toward improve-
ment in asthma control with a significant
improvement in lung function as assessed
by the Asthma Control Questionnaire
score. In patients with concomitant nasal
polyposis, reslizumab treatment was
associated with a significant improve-
ment in asthma symptoms. There was a
non-significant reduction in asthma exac-
erbations in the reslizumab group while
the adverse-event profile for reslizumab
and placebo were similar (Castro et al.,
2011). Benralizumab is a novel human-
ized afucosylated IgG1κ mAb indicated
for the potential treatment of asthma
and COPD that binds to a distinct epi-
tope within the extracellular domain of
recombinant human IL-5Rα (Ghazi et al.,
2012). Afucosylation is associated with
enhanced antibody-dependent cell cyto-
toxicity and benralizumab was found to
potently induce apoptosis in eosinophils
and basophils (Kolbeck et al., 2010).
Tissue eosinophils in bronchial biopsies of
patients with mild atopic asthma exhibited
intense immune positivity for benral-
izumab in contrast to resident mast cells,
which were negative. Other anti-IL-5mAb
act by neutralizing the effects of IL-5. In
contrast, benralizumab targets effector
cells, mainly eosinophils, and basophils.
A phase-1 study in subjects with mild
asthma demonstrated that intravenous
benralizumab rapidly induced near total
depletion of peripheral blood eosinophils
while exhibiting an adequate safety profile
and dose-proportional pharmacokinetics
(Busse et al., 2010).
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INTERLEUKIN-4 AND -13
Both IL-4 and IL-13 are important in
eosinophil accumulation and are key fac-
tors in IgE synthesis by B cells (Wills-Karp
et al., 1998) together with direct effects
on airway epithelial cells (Kuperman et al.,
2002). Several clinical trials of anti-IL-13
biologics reported disappointing clini-
cal outcomes although this cytokine is
widely regarded as central to asthmatic
inflammation. However, the latter conclu-
sion is almost exclusively based on stud-
ies that used animal-models of asthma.
Indeed, out of around 3000 peer-reviewed
publications implicating IL-13 as a cen-
tral mediator in asthma, only four relate
to direct evidence in human asthma
(Holgate, 2010). Importantly, in two of
these studies, elevated levels of IL-13 were
present in the sputum of around half
of asthmatic patients tested with no sig-
nificant association with disease severity
(Berry et al., 2004; Saha et al., 2008). It
is not surprising therefore that anti-IL-13
proved to be disappointing in asthma ther-
apy given that only half of the patients
recruited to a given clinical trial have
any likelihood of responding to this bio-
logic. The anti-IL-13mAb lebrikizumab
(Genentech/Chugai Pharmaceutical) has
recently been demonstrated to signifi-
cantly improve lung function in patients
with inadequately controlled asthma, but
only in a subgroup defined on the basis
of high serum levels of periostin (Corren
et al., 2011). The latter is a cellular matrix
protein that is released by airway epithe-
lial cells stimulated with IL-13. Periostin
exhibits effects on epithelial cells and
fibroblasts that may contribute to airway
remodeling in asthma (Takayama et al.,
2006; Sidhu et al., 2010) and may prove
to be useful as a biomarker to iden-
tify those subjects most likely to give a
positive clinical response to IL-13 antago-
nism. The recombinant human IL-4 vari-
ant, pitrakinra (Aerovant) competitively
inhibits the IL-4Ra receptor complex to
interfere with the actions of both IL-4
and IL-13 and initial clinical trials indi-
cated that such an approach may prove
beneficial in patients with atopic asthma
(Walsh, 2012). For example, a placebo-
controlled trial of inhaled pitrakinra in 534
patients with uncontrolled, moderate-to-
severe asthma reported significant effects
on exacerbations rates and symptom
scores in patients with an elevated blood
eosinophilia (Wenzel et al., 2010). In con-
trast, a study that examined AMG 317,
a fully humanized mAb to IL-4Rα, in
patients with moderate to severe asthma
reported no significant effects on primary
or secondary clinical endpoints. However,
clinically significant effects were observed
in those patients who had the most uncon-
trolled or symptomatic asthma (Corren
et al., 2010). It is interesting to note
that analysis of single nucleotide polymor-
phisms leading to for amino acid changes
in the 3′ end of the IL-4R α gene identified
a sub-group of patients with moderate-to-
severe asthma who were significantly more
responsive to pitrakinra therapy (Slager
et al., 2012).
TUMOUR NECROSIS FACTOR-α
Tumour necrosis factor (TNF)-α, an
important cytokine in innate immune
responses, has been implicated in several
chronic inflammatory diseases includ-
ing rheumatoid arthritis and Crohn’s
disease with anti-TNFα therapy proving
useful in these conditions. It is pro-
duced principally by macrophages while
other pro-inflammatory cells including
monocytes, dendritic cells, B lympho-
cytes, T cells, neutrophils, mast cells
and eosinophils, together with the struc-
tural cells fibroblasts, epithelial cells, and
smooth muscle cells represent significant
sources. TNF-α has pro-inflammatory
effects on eosinophils, neutrophils, T cells,
epithelial cells and endothelial cells and
may play a key role in amplifying air-
way inflammation through activation of
transcription factors such as NF-κB and
AP-1. TNF-α is expressed in biopsies
and lavage fluid from asthmatic air-
ways, particularly in patients with severe
asthma compared with those with well-
controlled disease. TNF-α is thought to
contribute to AHR, airway remodeling
and GC resistance in asthma and therefore
represents a potential target for ther-
apy (Walsh, 2011). Humanized murine
anti-TNF mAb (infliximab) and solu-
ble TNF receptor linked to human IgG1
(etanercept) have been developed and pre-
liminary clinical studies in asthma did
show significant improvements in lung
function, airway hypereactivity and exac-
erbation rate, particularly in patients with
severe asthma refractory to GC treatment
(Brightling et al., 2008). However, a more
recent clinical trial in 132 subjects with
moderate-to-severe persistent asthma
reported no significant differences
between etanercept and placebo for any
efficacy end-points although etanercept
was well-tolerated. In addition, the anti-
TNF biologic golimumab in patients with
severe uncontrolled persistent asthma
also reported negative clinical findings.
Importantly, this study was terminated
early due to unacceptable adverse events
including frequent serious infections,
eight malignancies and one death in
the active-treatment group compared
with the placebo group (Wenzel et al.,
2009). Overall it appears that TNF-α
inhibitors are effective in a sub-group of
patients with asthma, and again identifi-
cation of the correct patient population
may improve clinical outcomes (Matera
et al., 2010). However, the unfavorable
risk/benefit ratio exhibited by golimumab
does cast doubt on the future of anti-TNF
therapy in severe asthma.
CONCLUSION
The development of novel asthma anti-
inflammatory therapy based on target-
ing cytokines for the most part initially
proved to be disappointing. The major-
ity of biologics have proven inadequate in
the clinical setting in asthma even though
they were highly effective in animal mod-
els of asthma, most likely because the
artificially-induced airway inflammation
in the latter is not a true representation of
the wide spectrum of pathology observed
in asthmatic patients. The development
of discriminatory biomarkers and genetic
profiling may identify patients with par-
ticular sub-phenotypes of asthma allowing
therapy to be targeted to those most likely
to exhibit beneficial effects. This com-
bined with the development of biologics
aimed at the antagonism of more than one
cytokine, as exemplified by pitrakinra,may
prove a more effective approach.
REFERENCES
Barnes, P. J. (2008). Cytokine networks in asthma
and chronic obstructive pulmonary disease. J. Clin.
Invest. 118, 3546–3556.
Barnes, P. J. (2011). Pathophysiology of allergic
inflammation. Immunol. Rev. 242, 31–50.
Barrett, N. A., and Austen, K. F. (2009). Innate cells
and T helper 2 cell immunity in airway inflamma-
tion. Immunity 31, 425–437.
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery November 2012 | Volume 3 | Article 197 | 2
Walsh Eosinophil accumulation antagonism
Barthel, S. R., Johansson, M. W., McNamee, D. M.,
and Mosher, D. F. (2008). Roles of integrin acti-
vation in eosinophil function and the eosinophilic
inflammation of asthma. J. Leuk. Biol. 83, 1–12.
Berry, M. A., Parker, D., Neale, N., Woodman, L.,
Morgan, A., Monk, P., et al. (2004). Sputum
and bronchial submucosal IL-13 expression in
asthma and eosinophilic bronchitis. J. Allergy Clin.
Immunol. 114, 1106–1109.
Blanchard, C., and Rothenberg, M. E. (2009).
Biology of the eosinophil. Adv. Immunol. 101,
81–121.
Brightling, C., Berry, M., and Amrani, Y. (2008).
Targeting TNF-alpha: a novel therapeutic
approach for asthma. J. Allergy Clin. Immunol.
121, 5–10.
Busse, W. W., Katial, R., Gossage, D., Sari, S., Wang,
B., Kolbeck, R., et al. (2010). Safety profile, phar-
macokinetics, and biologic activity of MEDI-563,
an anti–IL-5 receptor antibody, in a phase I study
of subjects with mild asthma. J. Allergy Clin.
Immunol. 125, 1237–1244.
Castro, M., Mathur, S., Hargreave, F., Boulet, L. P.,
Xie, F., Young, J., et al. (2011). Reslizumab for
poorly controlled, eosinophilic asthma: a random-
ized, placebo-controlled study. Am. J. Respir. Crit.
Care Med. 184, 1125–1132.
Corren, J., Busse, W., Meltzer, E. O., Mansfield,
L., Bensch, G., Fahrenholz, J., et al. (2010). A
randomized, controlled, phase 2 study of AMG
317, an IL-4Ralpha antagonist, in patients with
asthma. Am. J. Respir. Crit. Care Med. 181,
788–796.
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat,
P. E., Parsey, M. V., Arron, J. R., et al. (2011).
Lebrikizumab treatment in adults with asthma. N.
Engl. J. Med. 365, 1088–1098.
Desai, D., and Brightling, C. (2009). Cytokine and
anti-cytokine therapy in asthma: ready for the
clinic? Clin. Exp. Immunol. 158, 10–19.
Egan, R.W., Umland, S. P., Cuss, F. M., and Chapman,
R. W. (1996). Biology of interleukin-5 and its
relevance to allergic disease. Allergy 51, 71–81.
Flood-Page, P., Swenson, C., Faiferman, I., Matthews,
J., Williams, M., Brannick, L., et al. (2007).
International Mepolizumab Study Group. A study
to evaluate safety and efficacy of mepolizumab in
patients with moderate persistent asthma. Am. J.
Respir. Crit. Care Med. 176, 1062–1071.
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A.
B., and Robinson, D. (2003). Eosinophil’s role
remains uncertain as anti-interleukin-5 only par-
tially depletes numbers in asthmatic airway. Am. J.
Respir. Crit. Care Med. 167, 199.
Ghazi, A., Trikha, A., and Calhoun, W. J. (2012).
Benralizumab -a humanized mAb to IL-5Rα with
enhanced antibody-dependent cell-mediated cyto-
toxicity -a novel approach for the treatment of
asthma. Expert Opin. Biol. Ther. 12, 113–118.
Haldar, P., Brightling, C. E., Hargadon, B., Gupta,
S., Monteiro, W., Sousa, A., et al. (2009).
Mepolizumab and exacerbations of refractory
eosinophilic asthma. N. Engl. J. Med. 360,
973–984.
Holgate, S. T. (2010). A look at the pathogenesis
of asthma: the need for a change in direction.
Discovery Med. 9, 439–447.
Kips, J. C., O’Conner, B. J., Langley, S. J., Woodcock,
A., Kerstjens, H. A. M., Postma, D. S., et al. (2003).
Effect of SCH55700, a humanised anti-human
interleukin-5 antibody in severe persistent asthma
– a pilot study. Am. J. Resp. Crit. Care Med. 167,
1655–1659.
Kolbeck, R., Kozhich, A., Koike, M., Peng, L.,
Andersson, C. K., Damschroder, M. M., et al.
(2010). MEDI-563, a humanized anti-IL-5 recep-
tor alpha mAb with enhanced antibody-dependent
cell-mediated cytotoxicity function. J. Allergy Clin.
Immunol. 125, 1344–1353.
Kuperman, D. A., Huang, X., Koth, L. L., Chang, G.
H., Dolganov, G. M., Zhu, Z., et al. (2002). Direct
effects of interleukin-13 on epithelial cells cause
airway hyperreactivity and mucus overproduction
in asthma. Nat. Med. 8, 885–889.
Leckie, M. J., ten Brinke, A., Khan, J., Diamant,
Z., O’Conner, B. J., Walls, C. M., et al. (2000).
Effects of an interleukin-5 blocking monoclonal
antibody on eosinophils, airway hypersonsive-
ness and the late asthmatic response. Lancet 356,
2144–2148.
Long, A. A. (2009). Monoclonal antibodies and other
biologic agents in the treatment of asthma. MAbs
1, 237–246.
Matera, M. G., Calzetta, L., and Cazzola, M. (2010).
TNF-alpha inhibitors in asthma and COPD: we
must not throw the baby out with the bath water.
Pulm. Pharmacol. Ther. 23, 121–128.
Molfino, N. A., Gossage, D., Kolbeck, R., Parker,
J. M., and Geba, G. P. (2012). Molecular and
clinical rationale for therapeutic targeting of
interleukin-5 and its receptor. Clin. Exp. Allergy 42,
712–737.
Nair, P., Pizzichini, M. M., Kjarsgaard, M., Inman,
M. D., Efthimiadis, A., Pizzichini, E., et al. (2009).
Mepolizumab for prednisone-dependent asthma
with sputum eosinophilia. N. Engl. J. Med. 360,
985–993.
O’Byrne, P. M. (2007). The demise of anti IL-5 for
asthma, or not. Am. J. Respir. Crit. Care Med. 176,
1059–1060.
Petsky, H. L., Kynaston, J. A., Turner, C., Li, A. M.,
Cates, C. J., Lasserson, T. J., et al. (2007). Tailored
interventions based on sputum eosinophils ver-
sus clinical symptoms for asthma in children and
adults. Coch. Database Sys. Rev. 18, CD005603.
Saha, S. K., Berry, M. A., Parker, D., Siddiqui, S.,
Morgan, A., May, R., et al. (2008). Increased
sputum and bronchial biopsy IL-13 expression
in severe asthma. J. Allergy Clin. Immunol. 121,
685–691.
Sidhu, S. S., Yuan, S., Innes, A. L., Kerr, S., Woodruff,
P. G., Hou, L., et al. (2010). Roles of epithe-
lial cell-derived periostin in TGF-β activation,
collagen production and collagen gel elasticity
in asthma. Proc. Natl. Acad. Sci. U.S.A. 107,
14170–14175.
Slager, R. E., Otulana, B. A., Hawkins, G. A., Yen,
Y. P., Peters, S. P., Wenzel, S. E., et al. (2012).
IL-4 receptor polymorphisms predict reduction
in asthma exacerbations during response to an
anti-IL-4 receptor α antagonist. J. Allergy Clin.
Immunol. 130, 516–522.
Takayama, G., Arima, K., Kanaji, T., Toda, S.,
Tanaka, H., Shoji, S., et al. (2006). Periostin:
a novel component of subepithelial fibrosis
of bronchial asthma downstream of IL-4 and
IL-13 signals. J. Allergy Clin. Immunol. 118,
98–104.
Walsh, G. M. (2010). Antagonism of eosinophil adhe-
sion in asthma. Recent Pat. Inflamm. Allergy Drug
Discov. 4, 210–213.
Walsh, G. M. (2011). Novel cytokine-directed thera-
pies for asthma. Discov. Med. 11, 283–291.
Walsh, G. M. (2012). An update on emerging
drugs for asthma. Expert Opin. Emerg. Drugs 17,
37–42.
Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet,
J., Busse, W., Dahlén, S. E., et al. (2009). A ran-
domized, double-blind, placebo-controlled study
of tumor necrosis factor-alpha blockade in severe
persistent asthma. Am. J. Respir. Crit. Care Med.
179, 549–558.
Wenzel, S. E., Ind, P.W., Otulana, B. A., Bleecker, E. R.,
Kuna, P., and Yen, Y. P. (2010). Inhaled pitrakinra,
an IL-4/IL-13 antagonist, reduced exacerbations in
patients with eosinophilic asthma. Ann. Congr. Eur.
Resp. Soc. 36:abstract P3980.
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B.,
Neben, T. Y., Karp, C. L., et al. (1998). Interleukin-
13: central mediator of allergic asthma. Science
282, 2258–2260.
Received: 17 October 2012; accepted: 02 November
2012; published online: 22 November 2012.
Citation: Walsh GM (2012) Antagonism of cytokine-
induced eosinophil accumulation in asthma. Front.
Pharmacol. 3:197. doi: 10.3389/fphar.2012.00197
This article was submitted to Frontiers in Experimental
Pharmacology and Drug Discovery, a specialty of
Frontiers in Pharmacology.
Copyright © 2012 Walsh. This is an open-access
article distributed under the terms of the Creative
Commons Attribution License, which permits use,
distribution and reproduction in other forums, pro-
vided the original authors and source are credited
and subject to any copyright notices concerning any
third-party graphics etc.
www.frontiersin.org November 2012 | Volume 3 | Article 197 | 3
